Retinol

HIV Infectious Disease

Small moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

59 Active assets in the HIV Infectious Disease cohort.

Asset / Sponsor	Phase	Rating
Raltegravir Helsinki University Central Hospital	Phase 4	A
Retrovir International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Phase 4	BBB
Efavirenz The Cleveland Clinic	Phase 4	BBB
NORVIR Giovanni Di Perri	Phase 4	BBB
Abacavir Germans Trias i Pujol Hospital	Phase 4	BBB

View all 46 →

Same molecule, other indications

Retinol is also rated in:

relapsing-remitting multiple sclerosisDormant

BB

Indicative · Phase 4

65 / 100

tuberculosisDormant

BB

Indicative · Phase 3

64 / 100

vitamin A deficiencyActive

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.